E-LIB Suche - Ergebnisse für: Moore, K.N.

1

44O Safety and efficacy results in patients who received do..:

Banerjee, S. ; Van Gorp, T. ; Konecny, G.E....
ESMO Open. 9 (2024) - p. 103551 , 2024

Link: https://doi.org/10.1016/..

2

40MO First-line (1L) durvalumab + carboplatin/paclitaxel (C..:

Van Nieuwenhuysen, E. ; Chon, H.S. ; Pepin, J. Thomes...
ESMO Open. 9 (2024) - p. 103540 , 2024

Link: https://doi.org/10.1016/..

3

Inclusion, diversity, equity, and access (IDEA) in gynecolo..:

Pothuri, B. ; Blank, S.V. ; Myers, T.K....
Gynecologic Oncology. 174 (2023) - p. 278-287 , 2023

Link: https://doi.org/10.1016/..

4

44P Real-world overall survival in second-line maintenance ..:

Moore, K.N. ; Perhanidis, J. ; Kalilani, L....
ESMO Open. 8 (2023) 1 - p. 100824 , 2023

Link: https://doi.org/10.1016/..

5

41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific an..:

Moore, K.N. ; O'Malley, D. ; Van Nieuwenhuysen, E....
ESMO Open. 8 (2023) 1 - p. 100821 , 2023

Link: https://doi.org/10.1016/..

6

157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC b..:

Sweis, R. ; Garralda, E. ; Saavedra Santa Gadea, O....
Immuno-Oncology and Technology. 16 (2022) - p. 100269 , 2022

Link: https://doi.org/10.1016/..

7

A phase II trial of bevacizumab and rucaparib in recurrent ..:

Jackson, C.G. ; Moore, K.N. ; Cantrell, L....
Gynecologic Oncology. 166 (2022) 1 - p. 44-49 , 2022

Link: https://doi.org/10.1016/..

8

197TiP First-in-human (FIH) phase I/II study of ubamatamab,..:

Moore, K.N. ; Bouberhan, S. ; Hamilton, E....
Immuno-Oncology and Technology. 16 (2022) - p. 100309 , 2022

Link: https://doi.org/10.1016/..

9

PARPi after PARPi in epithelial ovarian cancer:

Essel, K.G. ; Behbakht, K. ; Lai, T....
Gynecologic Oncology Reports. 35 (2021) - p. 100699 , 2021

Link: https://doi.org/10.1016/..

10

A phase Ib/II and pharmacokinetic study of EP0057 (formerly..:

Duska, L.R. ; Krasner, C.N. ; O'Malley, D.M....
Gynecologic Oncology. 160 (2021) 3 - p. 688-695 , 2021

Link: https://doi.org/10.1016/..

11

Phase III, randomized trial of mirvetuximab soravtansine ve..:

Moore, K.N. ; Oza, A.M. ; Colombo, N....
Annals of Oncology. 32 (2021) 6 - p. 757-765 , 2021

Link: https://doi.org/10.1016/..

12

Phase II study of durvalumab alone or in combination with A..:

Slomovitz, B. ; Bradley, W.H. ; Ghamande, S....
Gynecologic Oncology. 159 (2020) - p. 4-5 , 2020

Link: https://doi.org/10.1016/..

13

Impact of social services on depression and treatment outco..:

Evans, E.T. ; Essel, K.G. ; Johnston, S.E....
Gynecologic Oncology. 159 (2020) - p. 243 , 2020

Link: https://doi.org/10.1016/..

14

Population adjusted indirect comparison of the SOLO1 and PA..:

Vergote, I.B. ; Moore, K.N. ; Hettle, R....
Gynecologic Oncology. 159 (2020) - p. 19-20 , 2020

Link: https://doi.org/10.1016/..

15

Tolerability and adverse events experienced by women with o..:

Gillen, J. ; Miller, A. ; Moore, K.N....
Gynecologic Oncology. 159 (2020) - p. 15-16 , 2020

Link: https://doi.org/10.1016/..